Sign up to be part of ‘world-first’ global health study into Parkinson’s disease
Author: Parkinson's Life editorsPublished: 18 February 2016
Prep: Cook: Serves:
A pioneering project invites people with Parkinson’s to take part in a ‘world-first’ global study and help change healthcare – with just their smartphones
Do you own a smartphone? Then you too can become a citizen scientist and help improve our insight and understanding of Parkinson’s disease in a new innovative global study.
The ‘100 for Parkinson’s’ global study is a pioneering project that promises to gather data about all aspects of living with Parkinson’s, including sleep quality, mood, exercise, diet and stress levels. According to the organisers, it is a ‘world-first, ethics-approved, people-centred’ project.
Using a smartphone app specially developed for the study by uMotif, participants will track 10 important health aspects over a period of 100 days.
This data will provide key information for a team of academic researchers from leading Parkinson’s charities to learn more about how different health factors affect the disease, and could lead to new discoveries about the condition. For example, we may discover how factors such as the time of day that medications are taken affect a patient’s reflexes.
How to take part
Visit www.100forparkinsons.com, download the uMotif app from the App Store or Google Play and enter the code ‘100fp’ to unlock the study.
You must be aged 18 or over, own a smartphone or tablet and be willing to track your health for 100 days and donate your data.
Fighting Fit: tackling Parkinson’s in the workplace
We talk to the founders of a new programme in Buckinghamshire, UK
1 day ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”